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The tumor microenvironment (TME) corresponds to a complex and dynamic
interconnection between the extracellular matrix and malignant cells and their
surrounding stroma composed of immune and mesenchymal cells. The TME has
constant cellular communication through cytokines that sustain an inflammatory profile,
which favors tumor progression, angiogenesis, cell invasion, and metastasis. Although the
epithelial-mesenchymal transition (EMT) represents a relevant metastasis-initiating event
that promotes an invasive phenotype in malignant epithelial cells, its relationship with the
inflammatory profile of the TME is poorly understood. Previous evidence strongly suggests
that cyclooxygenase-2 (COX-2) overexpression, a pro-inflammatory enzyme related to
chronic unresolved inflammation, is associated with common EMT-signaling pathways.
This review article summarizes how COX-2 overexpression, within the context of the TME,
orchestrates the EMT process and promotes initial metastatic-related events.
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The Epithelial-Mesenchymal Transition (EMT) is a transient and reversible cellular modification
program (1), essential for various physiological and pathophysiological processes, like embryonic
development, stem cell differentiation, wound repair, and healing (2). EMT is characterized by the
transition from an epithelial to mesenchymal cellular phenotype, allowing cell migration and invasion (3).
Recent researches showed that EMT corresponds to a partial and transitory cellular event composed
of multiple stages (4, 5). The main phenotypic changes of epithelial cells that undergo the EMT
phenomenon, are the loss of adherens junctions based on E-cadherin and the disorganization of the
basal-apical polarity (6, 7). These phenotypic changes favor the expression of classic mesenchymal cell
markers, such as vimentin and N-cadherin, together with the increased expression of various
transcription factors related to EMT, which are identified both in vitro and in vivo (8, 9). Besides the
phenotypic changes described, structural and functional extracellular matrix (ECM) changes, mainlyJune 2021 | Volume 11 | Article 6867921
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beta (TGF-b), promote modifications of EMT-related cellular
markers expression (1, 9). Therefore, the EMT program strongly
depends on the microenvironment properties (2). Nonetheless, the
high heterogeneity of the cellular context limits to unravel of the full
spectrum of transcription factors that support all the cancer cell
modifications on gene expression and their specific biological
consequences (1, 4, 10). The main approaches have proposed the
existence of master zinc-finger transcription factors of the Snail
family, likewise, Twist and Zeb, as the central directors of EMT,
which, along with other transcription factors such as the YAP/TAZ
pathway, allow the repression of the epithelial phenotype (1, 2).
In the cancer context, tumor cells appropriate the EMT
program, which confers metastatic potential (2, 11). Previous
works proposed that one of the fundamental characteristics for
EMT development could correspond to their inflammatory profile
(12–14). Also, the unresolved-chronic inflammation might increase
the risk of cancer (10, 12, 15, 16). The presence of TGF-b and other
pro-inflammatory cytokines, such as tumor necrosis factor-alpha
(TNF-a), interleukin-6 (IL-6), and IL-8, induce the expression of
proteins associated with tumor promotion. The overexpression of
cyclooxygenase-2 (COX-2), the enzyme responsible for prostanoids
synthesis [both thromboxanes and prostaglandins (PGs)], has been
indicated as the leading promoter of the inflammatory profile of the
TME (17, 18). COX-2 is strongly related to chronic inflammatory
events without resolution (19, 20), tumor growth, angiogenesis, cell
invasion, metastasis, and chemoresistance, which lead to a low
patient survival rate (17, 21, 22). The inducible COX-2 gene is the
master switch that activates the inflammatory response (23). COX-2
protein is a critical mediator of inflammation that valuably
influences cell proliferation and migration, apoptosis evasion,
immunosuppression, tumor angiogenesis, invasion, and metastasis
(23–25) (Figure 1).Frontiers in Oncology | www.frontiersin.org 2Currently, it is comprehended that tumor cells can transit
through a hybrid EMT phenotype, named partial EMT (pEMT)
(26). This pEMT phenotype harbors epithelial and mesenchymal
characteristics, promoting a vaster invasive capacity of tumor cells
and their collective migration through the keeping of cell-cell
adherens junctions. Also, pEMT promotes cancer stemness and
drug resistance (27, 28). Cancer cells experiencing pEMT are
recognized in the early stages of tumor progression (28) and
strongly depend on the tumor context (29). Various
microenvironment components, like TGF-b , vascular
endothelial growth factor (VEGF), and the hypoxia-inducible
factor 1 (HIF-1), are responsible for promoting pEMT (30). We
suggest consulting the currently published review by Aggarwal
et al. (28) to detail analyze the relationship of the TME with the
induction and retention of pEMT.
Surprisingly, the mechanisms proposed for the plasticity and
maintenance of pEMT are related to the inflammatory cascade
resulting from COX-2 activity (30). An approximation of this
possible association was described by Lu et al. (31). They suggested
that the overexpression of COX-2 in the MCF-10F breast epithelial
cell line would induce a partial transformation towards a
mesenchymal phenotype. However, the relationship between COX-2
and the maintenance of pEMT state has not been elucidated.
Inflammation is one of the main contributors to the TME (32).
Various tumor promoters, oncogenes, and growth factors mediate
the COX-2 up-regulation. The COX-2 overexpression has been
reported in several human cancers that include breast (23), lung
(33), skin (34), esophagus (35), pancreas (36), prostate (37), bladder
(38), stomach (39), oral cavity (40, 41), and colorectal
adenocarcinoma (19, 42) (Table 1). In those studies, COX-2
expression was higher in patients with metastases. For example,
Harris et al. indicated that 87% of patients with breast cancer
metastases present high expression of COX-2 (23). Furthermore,GRAPHICAL ABSTRACT |June 2021 | Volume 11 | Article 686792
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stages T3 and T4 in esophageal cancer, concluding that COX-2 is
associated with tumor invasion (35). However, the most specific
data that support a cause-and-effect connection between COX-2
and tumorigenesis come from genetic studies in animal models (47).
Transgenic mice over-expressing COX-2 in epithelial mammary
glands, skin, and stomach develop malignancies and metastatic
tumors (48–50). Further, COX-2 overexpression can induce the
synthesis of proteases and integrins strongly associated with cancer
cell invasion in in different tumor types (51). Thus, COX-2 emerges
as a crucial factor for metastatic progression in different types of
tumors. Also, COX-2 expression is related to the intracellular
pathways activated by phosphatidylinositol 3-kinase (PI3K)/Akt,
Wnt/b-catenin, and nuclear factor-kappaB (NF-kB) that are
associated with tumor progression. The above suggests COX-2 is
a relevant element in promoting EMT by modulating the TGF-b
pathway (17, 52) and inducing the decrease or complete loss of E-
cadherin expression. Therefore, we propose COX-2 regulates E-
cadherin expression indirectly by encouraging NF-kB nuclear
translocation, which induces the down-regulation of E-cadherin
gene and the expression of EMT transcription factors (5).
Although are known various consequences of COX-2
overexpression in the TME, its relationship with the inhibition
of E-cadherin expression and EMT phenomenon is still poorly
understood. Throughout this review article, we propose signaling
pathways that could dominate the relationship between COX-2
(together with its metabolite PGE2, named COX-2/PGE2 axis)
and the promotion of EMT in the TME context.THE TUMOR MICROENVIRONMENT
(TME) AND INFLAMMATION
The TME of solid malignant tumors is a complex and dynamic
set of cancer cells, the ECM, surrounding blood vessels, tumor-
associated stromal cells (comprising many types of immune cells
and fibroblasts), and their secreted soluble factors (53, 54). The
interactions within the TME are essential for the heterogeneity ofFrontiers in Oncology | www.frontiersin.org 3cancer, clonal evolution, and the increase of multidrug resistance,
which leads to tumor progression and metastasis (55). During
tumor progression, cancer cells elude signals associated with
recovering the tissue homeostasis (21). The angiogenic nature of
TME is a relevant factor in tumor growth. Folkman described
that carcinomas in situ (less than 0.5 to 1 mm in diameter) would
have a nonangiogenic profile (56). However, during tumor
growth, a shift towards an inflammatory and hypoxic profile of
TME causes a strong dependence on angiogenic activity (21),
associated with metastatic growth (56). Thus, the TME
represents a complex scaffolding of multiple pro- and anti-
inflammatory signals without homeostatic balance.
A wide variety of cells participate in this pathologically
inflammatory process, which acquire different behaviors and
phenotypes in the TME. Among these cell types, tumor-
associated macrophages (TAMs) and carcinoma-associated
fibroblasts (CAFs) stand out. Within the TME, the COX-2
overexpression orchestrates this inflammatory profile in
various types of solid malignant tumors such as gastric cancer
(57), colorectal cancer (58), hepatocellular carcinoma (59),
melanoma (60), pancreatic cancer (36), endometrial cancer
(61), and squamous cell carcinoma of the neck and head (43).
Notably, colorectal adenocarcinoma research has helped
understand how the COX-2/PGE2 axis affects carcinogenesis
and tumor progression. Sada et al. indicates that COX-2/PGE2
overexpression can be observed early in benign lesions like
adenomas (62). Therefore, it seems like the sustained
overexpression of the COX-2/PGE2 axis favors adenocarcinoma
progression in the context of unresolved chronic inflammation (19).
Current investigations have demonstrated a decrease in
tumor progression and normalization of the TME through a
selective inhibition of COX-2 using the drug celecoxib (CXB)
(51, 63). CXB is an anti-inflammatory drug recognized by the
World Health Organization (WHO), which can inhibit COX-2
by blocking its functional activity. Based on the action of CXB, it
is possible to propose a dual treatment capable of modulating the
inflammatory nature of TME, and concomitant, promote the
immune response in anti-tumor therapies. Interestingly, thisFIGURE 1 | Increase in the COX-2 expression during tumor progression. COX-2 favors tumor progression from the initial stages of tumor promotion (dysplasia). In
advanced stages of tumor progression (carcinoma), COX-2 is overexpressed, and it is associated with partial EMT (pEMT) and EMT events.June 2021 | Volume 11 | Article 686792
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COX-2 co-localizes with PD-1 ligand (PD-L1) in peripheral
regions of the tumor and its surrounding inflammatory stroma
(64). These observations correlate with previous works that
demonstrated a positive relationship between the expression of
COX-2 and PD-L1 and a high number of metastatic events to
lymph nodes in lung adenocarcinoma (65), which could be
crucial to understand immunotherapy resistance (64, 66–68).
Furthermore, the development of synergic strategies targeting
the immune system and the inflammatory nature of the TME is
crucial, considering that EMT dramatically influences the
response to anti-tumor therapies (69, 70).Frontiers in Oncology | www.frontiersin.org 4COX-2 Overexpression in the Non-
Tumoral Cells of the TME: TAMs, Cancer
Stem Cells (CSCs), Myeloid-Derived
Suppressor Cells (MDSCs) and CAFs
Here, we describe the effects of the COX-2/PGE2 axis activity in
the TME, and how would induce the EMT program in cancer
cells (Figure 2).
COX-2 Overexpression in TAMs
TAMs, originated by the extravasation of monocytes attracted
due to inflammatory cytokines secreted by tumor cells (54, 71),
stimulate tumor growth, promote EMT and metastasis (54, 72).TABLE 1 | COX‐2 protein overexpression related to tumorigenesis and pro-tumoral activity of epithelial cancers (Refs, references).
System Histogenesis Organ Neoplasm COX-2 protein overexpression Biological and (or) Clinical Process Refs.
Digestive Epithelial Oral Cavity Oral Squamous
Cell Carcinoma
Promotes the release of PGE2, VEGF,
and CD147
Increased Cox-2 expression is associated with
the differentiation of human squamous epithelium
and is also related to tumor initiation,
progression, invasion, and metastasis.
40, 43
Digestive Epithelial Esophagus Squamous Cell
carcinoma
It was correlated with higher levels of
proteins related to cell proliferation,
such as Ki-67 and cyclin A. In contrast,
p27-staining was negatively correlated
with COX-2 Overexpression.
COX-2 overexpression is involved in an early
stage of squamous cell carcinogenesis of the
esophagus. Besides, COX-2 might regulate cell
proliferation and tumorigenesis of esophageal
epithelial tumors.
35
Digestive Epithelial Gastric Adenocarcinoma Associated with Helicobacter pylori
infection and the mutation of tumor
suppressor genes and also NF-kB
mutation.
COX-2 overexpression promotes the proliferation
of gastric cancer cells while inhibiting apoptosis.
Also, COX-2 overexpression might promote
angiogenesis and lymphatic metastasis, which
could be associated with cancer invasion and
immunosuppression.
39
Digestive Epithelial Colorectal Adenocarcinoma Induces increase of PGE2 production. Related to advanced tumor states and correlates
with poor clinical outcomes.
19
Digestive Epithelial Pancreas Adenocarcinoma May affect the epidermal growth factor
receptor (EGFR) signaling pathway.
Prostaglandin synthesis transactivates
the induction of EGFR phosphorylation,
thereby contributing to pancreatic
tumor proliferation.
Intrinsic cell role for COX-2 in tumor
initiation and progression through
activation of the PI3K/AKT pathway.
COX-2 overexpression promotes cell proliferation
and is correlated with tumor invasion,
angiogenesis, and resistance to apoptosis.
COX-2 overexpression correlated with a poor
prognosis for patients with pancreatic cancer.
36, 44
Respiratory Epithelial Lung Adenocarcinoma Promotes VEGF, MMP-2, and EGRF
expression.
COX-2 overexpression promotes tumor growth,
cell infiltration, and metastasis.
33
Urinary Epithelial Bladder Urothelial
Carcinoma
Suppresses the cytotoxic function of
immune cells.
COX-2 overexpression is associated with recurrence
and invasion of urothelial cancers, indicating its role
as a marker of aggressive behavior.
38, 45
Endocrine Epithelial Breast Adenocarcinoma Induces the transcription of CYP-19
and aromatase-catalyzed estrogen
biosynthesis.
COX-2 overexpression is associated with
mammary carcinogenesis’s essential features
(mutagenesis, mitogenesis, angiogenesis,
apoptosis inhibition, metastasis, and
immunosuppression).
23
Endocrine Epithelial Prostate Adenocarcinoma It is related to protein kinase C epsilon
type (PKCϵ) overexpression. Also,
COX-2 inhibits the PTEN pathway,
promoting NF-kB activation.
Stimulates angiogenesis through the
production of prostaglandins and
VEGF, which are known as pro-
angiogenic factors.
COX-2 expression is higher in metastatic
prostate tumors and is linked to poor patient
outcomes.
37, 46June 2021 | Volume 11 | Article 686792
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and it is accompanied by the expression of COX-2 in tumor cells
(73, 74). Gan et al. showed that TAMs co-cultivated with the
breast cancer cell line MDA-MB-231, overexpressed COX-2 and
induced cancer cell proliferation through the Akt pathway
activation. This effect caused the release of matrix
metallopeptidases (MMPs) to the TME and the expression of
transcription factors associated with EMT, which down-regulate
E-cadherin expression (75). In another study, Han et al. showed
that TAMs co-cultured with the osteosarcoma cell lines MG-63
and K-HOS promoted cancer cell migration and invasion in vitro
and in vivo (76). Also, these cell lines showed up-regulation of
COX-2 expression, activation of the STAT3 pathway, and
increased release of MMP-9 (76). The overexpression of COX-
2 in TAMs also up-regulates IL-6, which perpetuates high levels
of COX-2 in tumor cells (77). Recent studies proposed that the
expression of IL-6 in TAMs could increase the presence CSCs in
esophageal cancer, which is associated with an increase of
aldehyde dehydrogenases (ALDHs) expression. This
mechanism would promote autocrine signaling of IL-6,
together with the activation of the STAT3 pathway in CSCs
and tumor cells (15, 78).
Nonetheless, one of the biggest challenges for analyzing the
nature of TAMs corresponds to the modulation of their polarity
(that is, the differentiation between M1 and M2 phenotypes).Frontiers in Oncology | www.frontiersin.org 5Despite the association of the M2 phenotype of TAMs with anti-
inflammatory signals, subtypes of alternatively activated M2
endotype (AAM) were associate with tumorigenesis and tumor
progression (79). One of the M2 subtypes, known as M2a, has
been related to the wound healing process and could be
associated with EMT through TGF-b signaling (80). This
TAMs-M2 subtype also has been associated with an
immunosuppressive profile characterized by increased levels
and activation of STAT3 (81). Previous works suggested that
TAMs polarization signaling is orchestrated by STAT3/6, TGF-
b, and NF-kB, along with other pro-inflammatory pathways
closely related to the COX-2/PGE2 axis. Therefore, we
hypothesized that in cancers with a high inflammatory profile,
the coexistence of different polarities of TAMs could generate
cellular communications that favor EMT. Interestingly, Zhao et
al. informed that the COX-2 overexpression in TAMs causes up-
regulation of TGF-b1 on HCT-116 colon cancer cell line through
paracrine pathways (82). This observation was associated with
increased expression of the response gene to complement 32
(RGC-32) and the promotion of cell proliferation and migration
(82). Several studies propose that the phenotype of TAMs
represents a crucial element in the reprogramming profile of
their immunosuppressive behavior (83). Hence, we emphasized
the necessity of new efforts to explain the mechanisms
underlying TAMs acquire different phenotypes in cancer. Also,FIGURE 2 | The overexpression of the COX-2/PGE2 axis in cells within the tumor microenvironment (TME) promotes EMT in tumor cells through PGE2/EP4
paracrine signaling. The overexpression of the COX-2/PGE2 axis in cells within the TME promotes EMT in tumor cells through PGE2/EP4 paracrine signaling. The
COX-2/PGE2 axis overexpression favors the EMT phenomenon in tumor cells as a consequence of the inhibition of E-cadherin expression. The COX-2/PGE2
overexpression promotes signaling related to ROS and hypoxia, which explains the inflammatory profile of the tumor microenvironment (TME) in solid tumors.
Carcinoma-associated fibroblasts (CAFs); cancer stem cells (CSCs); myeloid-derived suppressor cells (MDSCs); and tumor-associated macrophages (TAMs).June 2021 | Volume 11 | Article 686792
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modulation in immuno-oncology therapies.
COX-2 Overexpression in CSCs
COX-2 is overexpressed in CSCs from different types of tumors,
which include head and neck squamous cell carcinoma
(HNSCC) and non-small cell lung cancer (NSCLC), among
others (17). Wu et al. showed that aberrant activation of the
COX-2/PGE2 axis promotes stemness through the activation of
the Wnt/b-catenin pathway in glioblastoma cells (84). Besides,
the presence of CSCs was related to radiotherapy resistance and
poor survival outcome (85). Interestingly, Majumder et al.
exhibited in a preclinical mouse model of breast cancer cell
line MCF-7, CSCmarkers associated with COX-2 expression and
EMT (86). PI3K and Akt pathways were common pathways
between COX-2 overexpression and EMT promotion. Moreover,
the authors established that the PGE2 receptor EP4 protected
these cells from apoptosis (86). This result suggests that COX-2
overexpression would induce genes related to progression of
CSCs phenotype during EMT.
Consequently, Tong et al. proposed that this COX-2
overexpression was associated with an increase in the CSCs
population in various types of tumors (15). Therefore, it has
been proposed that selective inhibition of the EP4 receptor
combined with other chemotherapeutic strategies, like
endocrine therapies, could be used synergistically against
chemo resistant cancers (87). Moreover, Lin et al. showed, in a
breast cancer model, that the inhibition of the PGE2/EP4
pathway reduces the chemoresistance and the CSCs population
in the TME (88). However, until now, the particular role of EP4
receptor in the EMT program has not been established. Terzuoli
et al. demonstrated in metastatic melanoma cell line WM266-4
and the metastatic NSCLC cells HCC4006 a large number of
CSCs that regulate the redox state of TME (89). Moreover, these
authors reported that ALDH expression was related to a higher
expression of the EMT markers, NF-kB factor, and COX-2/
PGE2 axis. Also, the authors proposed the ALDH3 blockade
could be a helpful therapy for cancers strongly inflamed and
associated with immunosuppression and stemness. Moreover,
they showed that this strategy could be beneficial when therapies
based on anti-PD-1/PD-L1 treatment did not have positive
outcomes (78, 89). Lastly, it is relevant to recognize that in
cancer cell lines from diverse origins, microRNAs (miRNAs)
could promote COX-2 overexpression in CSCs (86, 90–92). This
information considers possible alternative pathways beyond
those traditionally presented, such as stimulation with
lipopolysaccharides (LPS) and TNF-a, that could promote
COX-2 overexpression in CSCs. Therefore, new studies
examining how the inflammatory nature of TME modulates
COX-2 activity in CSCs would complement the currently
association between EMT and stemness (16, 93).
COX-2 Overexpression in MDSCs
Interestingly, MDSCs, generally described as HLA-DRlow/-
CD33+CCD11b+, are not present in normal tissue. Their
presence is strongly associated with tumor development and the
promotion of immuno-resistance in anti-tumor therapies (94, 95).Frontiers in Oncology | www.frontiersin.org 6Similarly, MDSCs are an essential cell type that promotes tumor
neovascularization and TME immunosuppression based on CD4+
and CD8+ T cell imbalance (91, 96). Li et al. demonstrated in the
nasopharyngeal cancer cell lines TW03 and CNE1, co-cultured
with MDSCs, that cell-cell contact stimulated the expression of
TGF-b and N2O cytokines in tumor cells (91). Furthermore, the
authors illustrated that PGE2 acted on MDSCs EP4 receptors,
activating p38-MAPK/extracellular-signal-regulated kinase (ERK)
pathways and inducing TGF-b secretion, which causes positive
feedback that stimulated EMT. Also, these signals promoted COX-
2/PGE2 axis overexpression, as well as b-catenin nuclear
translocation (91, 97). On the other hand, Yan et al. confirmed
in models of colorectal cancer, that the homeostatic imbalance of
TME affected the downstream signal of receptor-interacting
protein kinase 3 (RIPK3). RIPK3 was associated with
necroptosis promotion, causing the overexpression of the COX-
2/PGE2 axis and the induction of the immunosuppressive profile
in MDSCs (98). Lastly, Sangaletti et al. suggested that COX-2
overexpression in mammary carcinoma tumor cells, SN25A and
SN25ASP activates the IL-6 specifically in rich-collagen stromal
areas, inducing the MDSCs recruitment. Further, it was proposed
that COX-2 may induce the expression of tumor-associated
myelopoiesis factor expression called granulocyte-macrophage
colony-stimulating factor (GM-CSF), which allowed cell-cell
contact between MDSCs and tumor cells that also favored
EMT (99).
COX-2 Overexpression in CAFs
Solid tumors which present CAFs in the tumor stroma have a
worse prognosis (100). CAFs differ from normal fibroblasts for
the expression of smooth muscle a-actin (a-SMA). CAFs have a
phenotype characterized by an over-activated proliferative,
secretory, and migratory behavior and can perpetuate an
enabling framework for EMT development (13, 21, 54, 101)
and the progression of solid tumors (102). CAFs impact the
structural and secretory profile of the TME, resulting in the loss
of tissue homeostasis (13, 21, 102), along with the release of
chemo-attractant and immuno-escaping cytokines. Also, CAFs
promote the recruitment of myeloid cells, activation and
differentiation of MDSCs, and the polarization of TAMs
towards the M2 phenotype (13). Despite the notable advance
in understanding how CAFs may induce tumor progression,
their contribution in the modulation of the COX-2/PGE2 axis is
still not fully elucidated. These questions represent a relevant
challenge in the understanding of how CAFs modulate the EMT
process. Dudás et al. exposed the ability of CAFs to modify the
tumor stroma, co-cultivating oral squamous cell carcinoma cell
line SCC-25 with fibroblasts derived from the periodontal
ligament. This co-culture generated the transformation of
fibroblasts to CAFs after stimulation with IL-1b, which also
showed a marked nuclear translocation of NF-kB in CAFs. These
effects resulted in transcriptomic overexpression of COX-2 in
tumor cells (103). Surprisingly, IL-1b stimulation did not
generate an increase in the protein expression of inflammatory
mediators like IL-6 (103).
Giannoni et al. demonstrated that CAFs represented the
primary source of reactive oxygen species (ROS) in TME,June 2021 | Volume 11 | Article 686792
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would activate pro-inflammatory pathways in tumor cells
associated with NF-kB/COX-2/PGE2 and HIF-1 activation
and, along with it, raising the levels of small GTPase Rac1b.
Besides, the authors proposed ROS as the main EMT-inducing
factor (102). Alluringly, these events might explain the origin of
COX-2 overexpression in TAMs presented by Gan et al., where
CAFs might be one of the principal sources of pro-inflammatory
agents (75).
Further, Zhu et al. indicated CAFs from samples of
nasopharyngeal carcinoma (NPC) present COX-2/PGE2 axis
overexpression and correlate positively with TNF-a (104),
which together would promote metastasis. However, EMT
markers were unfortunately not evaluated in this model (104).
Therefore, further studies are needed to propose CAFs, the
primary source of COX-2/PGE2 activity of TME, as the main
inductor of EMT.
Repercussions of the COX-2
Overexpression on the EMT Process
of Tumor Cells
COX-2/PGE2 axis overexpression corresponds to a transversal
and critical event in the inflammatory nature of TME.
Consequently, the stromal cells that orchestrate tumor
development promote the over-activation of pro-inflammatory
signaling pathways in tumor cells, serving for tumor progression
and EMT (Figure 3). The evidence suggests a regulation of COX-2
overexpression through a battery of dynamic pro-inflammatory
signals emanated from the TME. These pro-inflammatory factors,
such as TNF-a and ROS, would stimulate tumor cells directly,
affecting COX-2/PGE2 axis overexpression and activation.
Furthermore, the same inflammatory context would generate the
nuclear translocation of NF-kB and HIF-1, causing an upward rise
in these pro-inflammatory factors. The rise of the ROS levels in the
TME causes the activation of the interferon regulatory factor 1
(IRF1) in tumor cells and may promote COX-2 activity and PGE2
synthesis (95). In addition, the bidirectional relationship between
IL-6 with COX-2/PGE2 overexpression would perpetuate
inflammatory events in tumor cells. PGE2 and its receptors play
a predominant role in promoting cancer progression. IL-6, also
known as interferon-beta2 (IFN-b2), is a pro-inflammatory
cytokine that plays a role in inflammation, immune response,
hematopoiesis, and cell differentiation. IL-6 production in
macrophages is directly stimulated by the COX2/PGE2 axis and
TGF-b, while IL-1b and LPS indirectly stimulate IL-6 production
via NF-kB activation. A positive association exists between
endogenous COX-2 metabolites and IL-6 synthesis in both in
vitro and in vivo models of several types of malignant neoplasms
(17, 105). IL-6 is the major cytokine in the TME with an extensive
range of biological activities. However, the IL-6 expression is
deregulated in cancer (106). The IL-6 overexpression is has
reported in various cancers, especially from epithelial
histogenesis (107) and hematological malignancies (108).
Interestingly, the high IL-6 levels in the TME serve to
associate chronic inflammation and cancer progression. IL-6
regulates various cancer hallmarks and multiple signalingFrontiers in Oncology | www.frontiersin.org 7pathways, such as JAK/STAT3, Ras/MAPK, and PI3K– PKB/
Akt. IL-6 regulates many gene products that cause tumor cell
growth, evasion of apoptosis, angiogenesis, metastasis, and
immunomodulation of the TME (105). Moreover, IL-6 protects
cancer cells from therapy-induced DNA damage, oxidative
stress, and apoptosis by facilitating the repair and induction of
counter signaling (antioxidant and anti-apoptotic/pro-survival)
pathways (105). Thus, IL-6 leads to the dysregulation of a
plethora of cellular activities that generally promote tumor
progression. Patients with high circulating IL-6 levels are
generally associated with a poor prognosis and shorter survival
(105) , mainly in breast carcinoma (105) , stomach
adenocarcinoma (109), and ovarian epithelial cancer (110).ACTIVATION OF PRO-INFLAMMATORY
PATHWAYS IN TUMOR CELLS IN
RESPONSE TO COX-2 OVEREXPRESSION
As discussed previously, TGF-b is the principal inducer of EMT.
However, previous studies have shown that TGF-b can modulate
the expression of VEGF, connective tissue growth factor (CTGF),
hepatocyte grow factor (HGF), fibroblast growth factor (FGF),
and TNF-a. These factors promote the up-regulation of the
COX-2/PGE2 axis, resulting in the induction of b-catenin
nuclear translocation in cancer cell lines (51, 95, 111–114) and
the expression of EMT transcription factors (75, 77, 95, 113).
Moreover, COX-2 overexpression increases the invasive capacity
of BGC-823 and SGC-7901 gastric cancer cell lines and may be
associated with gastric cancer metastasis (114). In addition,
COX-2 regulates the mammalian target of Rapamycin (mTOR)
factor and could be a helpful prognostic marker in gastric cancer
(114)). In summary, Figure 4 illustrates how the COX-2/PGE2
axis can modulate the classic pro-inflammatory pathways that
converge in E-cadherin inhibition and promote the
EMT program.
Neil et al. demonstrated in the murine mammary epithelial
cell line NMuMG that, after the EMT induction, the COX-2/
PGE2 axis overexpression decouples the canonical TGF-b
pathway (dependent on Smad2 and Smad3 factors) through
glycogen synthase kinase-3 beta (GSK3b). Interestingly, this
COX-2/PGE2 axis overexpression promotes its non-canonical
(Smad-independent) pathway, determining the aberrant binding
of TGF-b with the transcription factor NFkB (52). This activity
may equally be related to the stability of b-catenin through
GSK3b (15) and transcription factors of EMT (1). Also, it is
proposed that the increase of PGE2 expression PI3K/Akt and
ERK1/2 pathways, were strongly associated with oncogenic
signaling and EMT promotion (15, 52).
These observations turn out to agree with the results of Chen
et al. and Liu et al. (115, 116). They demonstrated NFkB
translocation in the gastric cancer cell line SGC-7901 due to
COX-2 overexpression, which down.regulates E-cadherin
expression via Snail. Along with this, they observed that the
silencing of COX-2 increased the mRNA and protein expression
of E-cadherin and Snail (115, 116). Furthermore, their resultsJune 2021 | Volume 11 | Article 686792
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COX-2 was necessary to regulate NFkB and Snail signals in
gastric cancer (116). These results support the idea proposed by
Garcıá de Herreros et al., who identified NF-kB translocation as a
relevant inductor of EMT transcription factors expression and E-
cadherin repression (5). However, these authors did not provide
a discussion about the origins of this phenomenon beyond the
presence of TGF-b (5). Dinicola et al. demonstrated in Caco-2
and HCT-8 colon cancer cells that COX-2/PGE2 axis
overexpression induces the activation of PI3K/Akt pathway,
and the concomitant NF-kB nuclear translocation, promoting
invasiveness (113). In addition, they evinced that after selective
COX-2 inhibition, E-cadherin levels normalize consistently with
previous studies (113). Furthermore, there is a close relationship
between NF-kB nuclear translocation and the redox metabolism
of cells within the TME, emphasizing its association in tumor
progression, EMT, and metastasis (88, 95).
As previously mentioned, another relevant event associated
with COX-2 overexpression corresponds to the presence of a
high ROS index within the TME. Concordantly, Giannoni et al.
showed high ROS levels induce NF-kB nuclear translocation that
activates the HIF-1 and Rac1b factors to promote a TME
favorable for tumor progression (102). Current studies indicate
that HIF-1 is a relevant factor in the activation of EMT and the
promotion of the hypoxic and inflammatory profile of the TME
(117). One of the central rationales indicates that this association
could promote the inflammatory cytokine-induced c-Myb
association towards areas of the promoter-type I collagen gene
(COL1A2). This event could generate an increase in the stromal
component of the TME and promote hypoxic areas with highFrontiers in Oncology | www.frontiersin.org 8expression of HIF1-a, proposing the independent analysis of the
COX-2 and c-Myb expression (110).
Various studies have described the role of microenvironmental
factors suchashypoxia inCOX-2 regulation (118).HIF-1alpha (HIF-
1a) is a dimeric protein complex that plays an integral role in low
oxygen concentrations (119). Likewise, HIF-1a is a significant
regulator of oxygen homeostasis within cells (119), activating
multiple genes involved in vasodilatation, angiogenesis,
neovascularization, cell survival, invasion, and tumor metastasis
(120). HIF-1a protein is overexpressed in multiple types of human
cancer, including lung, prostate, breast, pancreas, colon carcinoma,
and regional and distant metastases (120, 121). Also, overexpression
of HIF-1a can occur very early in carcinogenesis (120, 121). COX-
2up-regulationmay facilitate adaptation to cellular stress imposedby
hypoxia (118).
During hypoxia, COX-2 upregulation results in higher levels
of PGE2 (118). PGE2 can enhance HIF-1 transcriptional activity
and VEGF induction under hypoxic conditions (119). For
example, in hypoxic colorectal tumor cells, high levels of PGE2
enhance VEGF expression and HIF-1 transcriptional activity by
activating the mitogen-activated protein kinase (MAPK)
pathway, showing a potential positive feedback loop that
contributes to COX-2 up-regulation during hypoxia (118).
Further, HIF-1a activates the transcription of genes encoding
transferrin, VEGF, endothelin-1, and inducible nitric oxide
synthase (NOS2), which are implicated in vasodilation,
neovascularization, and tumor metastasis (121).
Interestingly, Basudhar et al. showed a NOS2/COX2 crosstalk
during tumor promotion and progression (122). Thereby, the
TME promotes various inflammatory pathways that induceFIGURE 3 | The COX-2/PGE2 axis overexpression is associated with EMT promotion in tumor cells and the presence of cancer-associated fibroblasts (CAFs) in the
tumor microenvironment (TME). The COX-2/PGE2 axis overexpression is associated with EMT promotion in cancer cells and the presence of CAFs in the TME. The
inflammatory profile of the TME favors the overexpression of the COX-2/PGE2 axis and promotes CAFs activation, which maintain the COX-2/PGE2 axis over-
activation. Also, the COX-2/PGE2 axis causing nuclear translocation of b-catenin and the induction of Snail/Slug/Zeb transcription factors expression that repress
the E-cadherin and promotes EMT.June 2021 | Volume 11 | Article 686792
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This increase of NO lead to COX-2 activity and the synthesis of
PGE2, which also induces NOS2 activity and promotes
angiogenesis , immunosuppression, and escape from
immunosurveillance (122). Therefore, the products of both
enzymes mutually regulate each other in such a way that low
and moderate amounts of NO are associated with tumor
invasion and EMT (123).
Besides, hypoxia promotes the inflammatory cytokine-
induced c-Myb expression towards areas of the promoter-type
I collagen gene (COL1A2). This event could generate an excessive
increase of the stromal component in the TME and promote
hypoxic areas with high expression of HIF1-a (124). Therefore,
we suggest to analyzing in detail the association between c-Myb
expression and COX-2.
Lastly, Echizen et al., proposed that the COX-2/PGE2 axis
overexpression in macrophages and bone marrow-derived cells
(BMDCs) up-regulates the transcription factor noxo1 in tumor
cells from colon adenocarcinoma. This signaling was due to the
TNF-a pathway and may generate an increase in ROS
production and stemness in gastrointestinal cancer cell lines
(125). Notably, Huang et al. demonstrated in the oxaliplatin-Frontiers in Oncology | www.frontiersin.org 9resistant HT29 colorectal cancer cell line that the alteration of
PGE2/EP4 signaling reduces intracellular ROS level and inhibits
stemness. Therefore, the overexpression of the COX-2/PGE2 axis
could promote chemoresistance and the cellular capacity to
counteract the potential damages by and elevated level of
intracellular ROS (126). Nevertheless, more studies are needed
to evaluate this adaptative mechanism against redox state with
the EMT program in tumor cells.EPIGENETIC MODULATION OF COX-2/
PGE2 AXIS AND THE EMT
TRANSCRIPTION FACTORS
The COX-2/PGE2 axis represents a target for epigenetic
modifications that allow its over-activation and perpetuates the
inflammatory nature of TME (104, 127, 128). Previous studies
suggested various miRNAs that can influence the generation of a
dynamic and favorable context for EMT development (128).
Surprisingly, several studies highlighted a considerable diversity
of influences of these miRNAs on the COX-2/PGE2 axis, whichFIGURE 4 | Intracellular pathways in tumor cells that associate COX-2/PGE2 axis overexpression with the promotion of EMT. Inflammatory components of the
tumor microenvironment (TME), such as TNF-a and TGF-b, promote the up-regulation of the COX-2/PGE2 axis. Besides, the COX-2/PGE2 axis maintains its
autocrine regulation through the activation of the PGE2 EP receptor. The COX-2/PGE2 axis overexpression activates the TGF-b non-canonical pathway (Smad-
independent) at the expense of inhibiting the canonical-Smad dependent signaling, along with activation of integrins and secretion of MMPs. Further, the COX-2/
PGE2 axis overexpression increases the intracellular ROS levels and activates NF-kB oncogenic functions, which promotes pro-inflammatory signaling pathways
and inhibits the GSK3bfactor. The inhibition of GSK3b triggers the activation of master-EMT transcription factors (snail, slug, zeb1/2, and twist), which inhibit E-
cadherin expression and finally facilitate the initiation and continuity of the EMT phenomenon. There is a potential EMT modulation associated with RhoA/
Rac1, according to the presence of microRNAs that would maintain a dynamic context-dependent role activating EMT transcription factors. #, their participation is
established, but their presence does not determine the process; P, phosphorylation.June 2021 | Volume 11 | Article 686792
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group these results according to how they finally affect the EMT
process. For example, there is evidence of EMT inhibition in
bladder cancer (129), oral cancer (130), esophageal squamous
cell carcinoma (131), lung cancer (132) and NSCLC (133),
cervical cancer (134), melanoma (135), and pancreatic cancer
(136), among others. Majumder et al., using the breast cancer cell
line MCF-7 observed stimulation of EMT by the miR-526b (86).
Therefore, it is necessary to recognize its implications according
to each case (89). Consistently, robust evidence indicates
epigenetic regulation of the COX-2/PGE2 axis, based on
miRNAs presence. Moreover, it is crucial to consider that
miRNAs also regulate EMT by inflammatory pathways,
directly affecting the canonical and non-canonical signaling of
TGF-band indirectly modulating EMT (127).
According to Mishan et al., there are various routes by which
miRNAs could promote the EMT program. Concordantly, MiR-
145, miR-335, miR-222, miR-150, and miR-34a have been
evidence as EMT promoters. Along with this, miR-200 and
miR-34 would be part of an EMT regulatory network (128).
These miRNAs are strongly associated with the maintenance of
the epithelial phenotype. However, as a result of signals such as
NF-kB, TGF-b, and HIF-1 in the cancer context, they also
promote the activation of the snail and Zeb transcription
factors families. This activation allows the up-regulation of the
Rac1/RhoA and PI3K pathways (137), which would indicate the
promotion of the mesenchymal phenotype necessary for cell
migration. Therefore, it is necessary to evaluate epigenetic
elements as possible therapeutic targets, notably considering
modulate the COX-2/PGE2 axis and could perpetuate the
EMT or pEMT program.DISCUSSION
Throughout this work, we have highlighted that Epithelial-
Mesenchymal Transition is a complex process regulated by
microenvironmental demands rather than the internal signaling
of each tumor cell. The evidence collected in this work recognizes
the COX-2/PGE2 axis as the main driver of EMT and pEMT. The
COX-2/PGE2 axis overexpression has an essential role in activating
signaling pathways associated with most processes that induce
tumor growth and metastasis. Moreover, we consider the COX-2/
PGE2 axis not only as a great promoter of tumor progression but
metastasis-initiating processes, like EMT. Consequently, it is
necessary to carry out clinical studies that consider the potential
inhibition of the COX-2/PGE2 axis and EMTmarkers as metastasis
inhibitory treatments in oncology.
Current therapeutic strategies directed to repress the COX-2
overexpression are focused on the inhibition of metabolites
resulting from the activity of the COX-2/PGE2 axis. Thus, the
specific blockade of the EP4 receptor, has been proposed,
showing better results when is with chemotherapeutic
regimens or selective COX-2 blocking through CXB (88, 127).
Despite this, the selective COX-2 inhibitors have been
extensively investigated in diverse types of cancer, generatingFrontiers in Oncology | www.frontiersin.org 10promising effects as adjuvant therapy. To be specific, it was
recognized that CXB reduces the risk of the malignant
transformation of colon adenomas towards adenocarcinomas
in familial adenomatous polyposis (138). Interestingly, Egashira
et al. demonstrated in the HCT-116 colon cancer cell line that
CXB inhibits the Wnt/b-catenin signaling pathway, further
reducing recurrence after colectomy (139). However, COX-2
inhibitors have been questioned for their potential risk of
cardiovascular adverse events. Auspiciously, recent studies
showed that CXB has better results according to their
gastrointestinal and renal security than other NSAIDs such as
ibuprofen and naproxen (140, 141). Also, CXB is associated with
fewer cardiovascular adverse events than other COX-2 selective
inhibitors, such as rofecoxib (142).
Hashemi Goradel et al. illustrated factors that can modulate
the COX-2 targeted therapy, such as type of cancer, type of COX-
2 inhibitor, the dose of COX-2 inhibitor, among others (17).
Surprisingly, these factors might be associated with the
heterogeneous results shown by clinical trials that used CXB as
an anti-tumor adjuvant. For example, Hamy et al., based on the
exploratory analysis of the REMAGUS02 Trial, indicated that
CXB improves the overall survival (OS) and event-free
progression (EFP) in breast cancer patients only with high
COX-2 expression. Additionally, they indicated the importance
of estrogen-receptor status previously the CXB administration
(142). Guo et al. demonstrated that the platinum and fluorouracil
therapy combined with CXB improved the OS and EFP in
patients with advanced and recurrent gastric cancer with COX-
2 overexpression (143). However, Kelly et al. evidenced in
BOXIT randomized phase III Clinical Trial that CXB does not
improve recurrence-free rates of the standard treatment against
transitional bladder cell carcinoma (144). Similar results were
presented by Bi et al. in Phase II randomized Clinical Trial
among patients with NSCLC, without evidence differences
between concurrent chemoradiation with or without CXB
administration (145). The heterogeneous results of CXB effects
in these Clinical Trials could be related to distinct signaling
pathways altered in each type of cancer. For example, Zhang et al.
showed that the crucial signaling altered in NSCLC was EGF
receptor (EGFR). Also, they demonstrated that the use of CXB
improves the overall response rate (ORR) (146). Therefore, more
studies are required to describe the best therapeutic regimen
according to the potential synergism between chemotherapeutic
or immunotherapeutic strategies with CXB as an adjuvant.
Other therapeutic strategies with promising prospects are
using the association of COX-2 inhibitors and immune
checkpoint blockade as a potential choice (147). Several clinical
trials of COX-2 inhibitor combination therapy with immune
checkpoint inhibitors in cancers have been described.
Specifically, the combinations of COX-2 inhibitor inhibitors
and anti-programmed cell death protein-1 (anti-PD-1)
immunotherapy can promote tumor regression. Wang et al.
demonstrated that using COX-2 inhibitor with anti-PD-
1 antibody, the objective response rate at six months
significantly improved in patients with metastatic melanoma
and NSCLC, compared with the anti-PD-1 strategy (148).June 2021 | Volume 11 | Article 686792
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prognostic effect of a high neutrophil-lymphocyte ratio
by prolonging time-to-progression in patients with melanoma
(148). Concordantly, Shimizu et al. demonstrated in resected
tissue specimens of lung adenocarcinoma that PD-L1 correlated
with COX-2 expression, and most cancer cells that express PD-
L1 also co-expressed COX-2. However, COX-2 inhibition did
not impact PD-L1 expression in NSCLC cell lines as assessed
in vitro. These experimental results can be interpreted as
suggesting that COX-2 inhibition does not affect PD-L1
expression (149). Therefore, COX-2 inhibition possesses little
influence of the efficacy of immune checkpoint inhibitors in lung
cancer treatment. Despite this, other studies have shown
encouraging results for this combined therapeutic strategy in
breast cancer and melanoma (68, 150). News perspectives for the
combined use (COX-2 inhibitor and immune checkpoint
inhibitors) as a practical therapeutic strategy should be
sustained with more evidence in the future.
In conclusion, we propose that COX-2/PGE2 axis
overexpression should be recognized as an initial promoter of
metastasis. The COX-2/PGE2 axis corresponds to the main
promotor of the inflammatory profi le of the tumor
microenvironment and tumor progression. Hence, its
inhibition associated with other therapies may provideFrontiers in Oncology | www.frontiersin.org 11beneficial results, especially for those tumors that present
overexpression of COX-2. Its potential inhibition could mean
the reversal of the EMT or pEMT phenomenon and the
impediment of metastases.AUTHOR CONTRIBUTIONS
All authors contributed equally to the conception of the work.
FG-V drafted and organized the manuscript. All authors
contributed to the article and approved the submitted version.FUNDING
This work was partially supported by Project FONDECYT
1150397 (VM).ACKNOWLEDGMENTS
FG-V acknowledges partial support from CONICYT-PFCHA/
Doctorado Nacional 2019-Folio 21190421.REFERENCES
1. Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, Zaravinos
A. Emt Factors and Metabolic Pathways in Cancer. Front Oncol (2020)
10:499. doi: 10.3389/fonc.2020.00499
2. Singh M, Yelle N, Venugopal C, Singh SK. Emt: Mechanisms and
Therapeutic Implications. Pharmacol Ther (2018) 182:80–94.
doi: 10.1016/j.pharmthera.2017.08.009
3. Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic
Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Cell
Stem Cell (2019) 24:65–78. doi: 10.1016/j.stem.2018.11.011
4. Cook DP, Vanderhyden BC. Context Specificity of the EMT Transcriptional
Response. Nat Commun (2020) 11:1–9. doi: 10.1038/s41467-020-16066-2
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et al. Latest Advances in Targeting the Tumor Microenvironment for Tumor
Suppression. Int J Mol Sci (2019) 20:4719. doi: 10.3390/ijms20194719
102. Giannoni E, Bianchini F, Calorini L, Chiarugi P. Cancer Associated
Fibroblasts Exploit Reactive Oxygen Species Through a Pro-Inflammatory
Signature Leading to Epithelial Mesenchymal Transition and Stemness.
Antioxidants Redox Signal (2011) 14:2361–71. doi: 10.1089/ars.2010.3727
103. Dudás J, Fullár A, Bitsche M, Schartinger V, Kovalszky I, Sprinzl GM, et al.
Tumor-Produced, Active Interleukin-1bregulates Geneexpression in
Carcinoma-Associated Fibroblasts. Exp Cell Res (2011) 317:2222–9.
doi: 10.1016/j.yexcr.2011.05.023
104. Zhu Y, Shi C, Zeng L, Liu G, JiangW, Zhang X, et al. High COX-2 Expression
in Cancer-Associated Fibiroblasts Contributes to Poor Survival and
Promotes Migration and Invasiveness in Nasopharyngeal Carcinoma. Mol
Carcinogen (2020) 59:265–80. doi: 10.1002/mc.23150
105. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of Interleukin-6 in
Cancer Progression and Therapeutic Resistance. Tumour Biol (2016)
37:11553–72. doi: 10.1007/s13277-016-5098-7
106. Kaur S, Bansal Y, Kumar R, Bansal G. A Panoramic Review of IL-6:
Structure, Pathophysiological Roles and Inhibitors. Bioorg Med Chem
(2020) 28:115327. doi: 10.1016/j.bmc.2020.115327June 2021 | Volume 11 | Article 686792
Gómez-Valenzuela et al. Cyclooxygenase-2 Overexpression Promotes Epithelial-Mesenchymal Transition107. Zeng J, Tang ZH, Liu S, Guo SS. Clinicopathological Significance of
Overexpression of Interleukin-6 in Colorectal Cancer. W. J Gastroenterol
(2017) 23:1780–6. doi: 10.3748/wjg.v23.i10.1780
108. Li Y, Du Z, Wang X, Wang G, Li W. Association of IL-6 Promoter and
Receptor Polymorphisms With Multiple Myeloma Risk: A Systematic
Review and Meta-Analysis. Genet Test Mol Biomarkers (2016) 20:587–96.
doi: 10.1089/gtmb.2015.0169
109. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al.
Clinical Significance of Interleukin-6 (IL-6) in the Spread of Gastric Cancer:
Role of IL-6 as a Prognostic Factor. Gastric Cancer (2005) 8:124–31.
doi: 10.1007/s10120-005-0315-x
110. Guo Y, Nemeth J, O’Brien C, Susa M, Liu X, Zhang Z, et al. Effects of
Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer. Clin
Cancer Res (2010) 16:5759–69. doi: 10.1158/1078-0432.CCR-10-1095
111. Guan X. Cancer Metastases: Challenges and Opportunities. Acta Pharm Sin
B (2015) 5:402–18. doi: 10.1016/j.apsb.2015.07.005
112. Ogunwobi OO, Wang T, Zhang L, Liu C. Cyclooxygenase-2 and Akt Mediate
Multiple Growth-Factor-Induced Epithelial-Mesenchymal Transition in
Human Hepatocellular Carcinoma. J Gastroenterol Hepatol (2012) 27:566–
78. doi: 10.1111/j.1440-1746.2011.06980.x
113. Dinicola S, Masiello MG, Proietti S, Coluccia P, Fabrizi G, Catizone A, et al.
Nicotine Increases Colon Cancer Cell Migration and Invasion Through
Epithelial to Mesenchymal Transition (EMT): COX-2 Involvement. J Cell
Physiol (2018) 233:4935–48. doi: 10.1002/jcp.26323
114. Xiang L, Wang W, Zhou Z, Lv M, Tao L, Ni T, et al. COX-2 Promotes
Metastasis and Predicts Prognosis on Gastric Cancer Via Regulating Mtor.
Biomark Med (2020) 14:421–32. doi: 10.2217/bmm-2019-0357
115. Chen Z, Liu M, Liu X, Huang S, Li L, Song B, et al. COX-2 Regulates E-
cadherin Expression Through the NF-kb/Snail Signaling Pathway in Gastric
Cancer. Int J Mol Med (2013) 32:93–100. doi: 10.3892/ijmm.2013.1376
116. Liu XJ, Chen ZF, Li HL, Hu ZN, Liu M, Tian AP, et al. Interaction Between
Cyclooxygenase-2, Snail, and E-cadherin in Gastric Cancer Cells. World J
Gastroenterol (2013) 19:6265–71. doi: 10.3748/wjg.v19.i37.6265
117. Wei Q, Qian Y, Yu J, Wong CC. Metabolic Rewiring in the Promotion of
Cancer Metastasis: Mechanisms and Therapeutic Implications. Oncogene
(2020) 39:1–18. doi: 10.1038/s41388-020-01432-7
118. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct Transcriptional
Up-Regulation of Cyclooxygenase-2 by Hypoxia-Inducible Factor (HIF)-1
Promotes Colorectal Tumor Cell Survival and Enhances HIF-1
Transcriptional Activity During Hypoxia. Cancer Res (2006) 66:6683–91.
doi: 10.1158/0008-5472.CAN-06-0425
119. Masoud GN, Li W. Hif-1alpha Pathway: Role, Regulation and Intervention
for Cancer Therapy. Acta Pharm Sin B (2015) 5:378–89. doi: 10.1016/
j.apsb.2015.05.007
120. Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1a in the
Tumorigenesis and Progression of Pancreatic Cancer. Cancer Cell Int
(2020) 20:273. doi: 10.1186/s12935-020-01370-0
121. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al.
Overexpression of Hypoxia-Inducible Factor 1a in Common Human
Cancers and Their Metastases. Cancer Res (1999) 59:5830–5.
122. Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA,
et al. Coexpression of NOS2 and COX2 Accelerates Tumor Growth and
Reduces Survival in Estrogen Receptor-Negative Breast Cancer. PNAS (2017)
114:13030–35. doi: 10.1073/pnas.1709119114
123. Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn
SA. The Role of Nitric Oxide in Cancer: Master Regulator or Not? Int J Mol
Sci (2020) 21:9393. doi: 10.3390/ijms21249393
124. Xie R, Yang Y, Zhang H, Liu H, Guo J, Qin H, et al. C-Myb and its Effector COX-
2 as an Indicator Associated With Prognosis and Therapeutic Outcome in
Colorectal Cancer. J Cancer (2019) 10:1601–10. doi: 10.7150/jca.27261
125. Echizen K, Oshima H, Nakayama M, Oshima M. The Inflammatory
Microenvironment That Promotes Gastrointestinal Cancer Development
and Invasion. Adv Biol Regul (2018) 68:39–45. doi: 10.1016/
j.jbior.2018.02.001
126. Huang H, Aladelokun O, Ideta T, Giardina C, Ellis LM, Rosenberg DW.
Inhibition of PGE 2/EP4 Receptor Signaling Enhances Oxaliplatin Efficacy in
Resistant Colon Cancer Cells Through Modulation of Oxidative Stress. Sci
Rep (2019) 9:1–11. doi: 10.1038/s41598-019-40848-4Frontiers in Oncology | www.frontiersin.org 14127. Cebola I, Peinado MA. Epigenetic Deregulation of the COX Pathway in
Cancer. Prog Lipid Res (2012) 51:301–13. doi: 10.1016/j.plipres.2012.02.005
128. Mishan MA, Khazeei Tabari MA, Zargari M, Bagheri A. MicroRNAs in the
Anticancer Effects of Celecoxib: A Systematic Review. Eur J Pharmacol
(2020) 882:173325. doi: 10.1016/j.ejphar.2020.173325
129. Liu X, Wu Y, Zhou Z, Huang M, Deng W, Wang Y, et al. Celecoxib Inhibits
the Epithelial-to-Mesenchymal Transition in Bladder Cancer Via the
miRNA-145/TGFBR2/Smad3 Axis. Int J Mol Med (2019) 44:683–93.
doi: 10.3892/ijmm.2019.4241
130. D’Souza W, Kumar A. microRNAs in Oral Cancer: Moving From Bench to
Bed as Next Generation Medicine. Oral Oncol (2020) 111:104916.
doi: 10.1016/j.oraloncology.2020.104916
131. Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, et al. MiR-26a and miR-144 Inhibit
Proliferation and Metastasis of Esophageal Squamous Cell Cancer by
Inhibiting Cyclooxygenase-2. Oncotarget. (2016) 7:15173–86. doi: 10.3892/
or.2014.3648
132. Monteleone NJ, Lutz CS. miR-708-5p Targets Oncogenic Prostaglandin E2
Production to Suppress a Pro-Tumorigenic Phenotype in Lung Cancer Cells.
Oncotarget. (2020) 11:2464–83. doi: 10.18632/oncotarget.27614
133. Lai XN, Li J, Tang LB, Chen WT, Zhang L, Xiong LX. MiRNAs and
LncRNAs: Dual Roles in TGF-b Signaling-Regulated Metastasis in Lung
Cancer. Int J Mol Sci (2020) 21:1193. doi: 10.3390/ijms21041193
134. Miao J, Regenstein JM, Xu D, Zhou D, Li H, Zhang H, et al. The Roles of
microRNA in Human Cervical Cancer. Arch Biochem Biophys (2020)
690:108480. doi: 10.1016/j.abb.2020.108480
135. Panza E, Ercolano G, De Cicco P, Armogida C, Scognamiglio G, Botti G,
et al. MicroRNA-143-3p Inhibits Growth and Invasiveness of Melanoma
Cells by Targeting Cyclooxygenase-2 and Inversely Correlates With
Malignant Melanoma Progression. Biochem Pharmacol (2018) 156:52–9.
doi: 10.1016/j.bcp.2018.08.008
136. Gong R, Jiang Y. Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma.
Front Oncol (2020) 10:309. doi: 10.3389/fonc.2020.00309
137. Gkretsi V, Stylianopoulos T. Cell Adhesion and Matrix Stiffness:
Coordinating Cancer Cell Invasion and Metastasis. Front Oncol (2018)
8:145. doi: 10.3389/fonc.2018.00145
138. Kim B, Giardiello FM. Chemoprevention in Familial Adenomatous
Polyposis. Best Pract Res Clin Gastroenterol (2011) 25:607–22.
doi: 10.1016/j.bpg.2011.08.002
139. Egashira I, Takahashi-Yanaga F, Nishida R, Arioka M, Igawa K, Tomooka K,
et al. Celecoxib and 2, 5-Dimethylcelecoxib Inhibit Intestinal Cancer Growth
by Suppressing the Wnt/b-Catenin Signaling Pathway. Cancer Sci (2017)
108:108–15. doi: 10.1111/cas.13106
140. Varrassi G, Pergolizzi JV, Dowling P, Paladini A. Ibuprofen Safety at the
Golden Anniversary: Are All NSAIDs the Same? A Narrative Review. Adv
Ther (2020) 37:61–82. doi: 10.6084/m9.figshare.10075727
141. Li M, Yu C, Zeng X. Comparative Efficacy of Traditional non-Selective
NSAIDs and Selective Cyclo-Oxygenase-2 Inhibitors in Patients With Acute
Gout: A Systematic Review and Meta-Analysis. BMJ Open (2020) 10:
e036748. doi: 10.1136/bmjopen-2019-036748
142. Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, et al. Celecoxib
With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen
Outcomes Differentially by COX-2 Expression and ER Status: Exploratory
Analysis of the REMAGUS02 Trial. J Clin Oncol (2019) 37:624–35.
doi: 10.1200/JCO.18.00636
143. Guo Q, Li Q, Wang J, Liu M, Wang Y, Chen Z, et al. A Comprehensive
Evaluation of Clinical Efficacy and Safety of Celecoxib in Combination With
Chemotherapy in Metastatic or Postoperative Recurrent Gastric Cancer
Patients: A Preliminary, Three-Center, Clinical Trial Study. Med
(Baltimore) (2019) 98:e16234. doi: 10.1097/MD.0000000000016234
144. Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, et al.
BOXIT—a Randomised Phase III Placebo-Controlled Trial Evaluating the
Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma
of the Bladder (CRUK/07/004). Eur Urol (2019) 75:593–601. doi: 10.1016/
j.eururo.2018.09.020
145. Bi N, Liang J, Zhou Z, Chen D, Fu Z, Yang X, et al. Effect of Concurrent
Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on
Survival Among Patients With Non–Small Cell Lung Cancer With and
Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized ClinicalJune 2021 | Volume 11 | Article 686792
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a-SMA alpha-actin of smooth muscle
AAM alternatively activated M2 endotype
ALDHs aldehyde dehydrogenases
BMDCs bone marrow-derived cells
CAFs carcinoma-associated fibroblasts
COL1A2 type I collagen gene
COX-2 cyclooxygenase-2
CSCs cancer stem cells




EGF epidermal growth factor
EGFR epidermal growth factor receptor
EMT epithelial-mesenchymal transition
ERK extracellular-signal-regulated kinase
FGF fibroblast grow factor
GM-CSF granulocyte-macrophage colony-stimulating factor
GSK3b glycogen synthase kinase 3 beta
HGF hepatocyte grow factor
HIF-1 hypoxia-inducible factor-1
HNSCC head and neck squamous cell carcinoma
IFN-b2 interferon-beta2
IL interleukin
IRF1 interferon regulatory factor 1
LPS lipopolysaccharides
MAPK mitogen-activated protein kinase
MDSCs myeloid-derived suppressor cells
MMPs matrix metallopeptidases
miRNA microRNA




NSAID non-steroidal anti-inflammatory drug
NSCLC non-small cell lung cancer
ORR overall response rate
PD-1 programmed death protein-1
PD-L1 programmed death protein-1 ligand
PGs prostaglandins
pEMT partial epithelial-mesenchymal transition
PKCϵ protein kinase C epsilon type
PI3K phosphatidylinositol 3-kinase
RGC-32 complement response gene 32
RIPK3 receptor-interacting protein kinase 3
ROS reactive oxygen species
STAT3 signal transducer and activator of transcription 3
TAMs tumor-associated macrophages
TGF-b transforming growth factor-beta
TME tumor microenvironment
TNF-a tumor necrosis factor-alpha
VEGF vascular endothelial growth factor
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